These analyses indicate that the co-expression between MYBL2 and EIF4EBP1 is not restricted to glioblastomas, suggesting that MYBL2 might represent a more general regulatory mechanism driving EIF4EBP1 expression in different cancer entities. This evidence concerns the gene EIF4EBP1 and cancer.